Breaking News
Investing Pro 0
Final hours: unlock premium data with Claim 60% OFF

Medtronic doubles profit, lifts full-year outlook after strong Q2

Published Nov 21, 2023 07:56AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters.
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio

Medtronic (NYSE:MDT)'s second-quarter earnings report revealed a significant increase in profits and a raised forecast for the full year following a robust performance that exceeded analysts' expectations. The medical device company's adjusted earnings per share (EPS) hit $1.25, surpassing the predicted figures by seven cents. This surge is attributed to a 5.3% rise in revenues, reaching $7.98 billion, with profits doubling to $909 million for the quarter ending October 27.

The Fridley-based firm's financial success is spread across its diverse product portfolio, including cardiovascular, medical-surgical, neuroscience, and diabetes sectors. This comprehensive growth led to a revised forecast for the full year. CFO Karen Parkhill announced an increase in the expected organic revenue growth rate from 4.5% to 4.75%. Additionally, Medtronic now anticipates its adjusted EPS to be between $5.13 and $5.19, slightly up from the previous estimate of $5.08 to $5.16.

CEO Geoff Martha attributes this strong performance to consistent growth across all sectors and regions, bolstered by significant product launches. The company's pre-market shares reflected this positive momentum, with an almost 2% increase.

Investors are responding favorably to Medtronic's updated tax effects and currency exchange considerations, which have contributed to the improved financial forecasts. With these revised projections, Medtronic positions itself for continued success in the highly competitive medical device industry.

InvestingPro Insights

Medtronic's recent earnings report, which showcased a noteworthy uptick in profits and a raised full-year forecast, aligns with several key metrics and InvestingPro Tips that may further interest investors. The company's market capitalization stands robust at $100.0 billion, reflecting its significant presence in the healthcare equipment and supplies industry. The adjusted price-to-earnings (P/E) ratio for the last twelve months as of Q1 2024 is at 22.74, suggesting a potentially more attractive valuation compared to the current P/E ratio of 27.79.

InvestingPro Tips highlight Medtronic's high earnings quality, with free cash flow surpassing net income, indicating strong financial health. Additionally, the company's consistent history of dividend growth, with increases for 9 consecutive years and maintained payments for 47 years, is a testament to its financial stability and shareholder commitment. This is further substantiated by a dividend yield of 3.69% as of late September 2023. With a total of 8 additional InvestingPro Tips available, investors can gain deeper insights into Medtronic's financial nuances by exploring the full list on the InvestingPro platform.

For those considering a deeper dive into Medtronic's financials, the InvestingPro subscription is now available at a special Black Friday sale with discounts of up to 55%. This offer provides access to an expansive array of analytics and metrics that can empower informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Medtronic doubles profit, lifts full-year outlook after strong Q2

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your profile, will be public on and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email